p53 expression is associated with malignant potential in xenograft tissues of a fibrosarcoma mouse model

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 973-978

  Skalicky, S E ^a   Ow, K ^a   Hannan, M ^a   Russell, P J ^a   Crowe, P J ^a   Yang, Jia Lin ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Animal model; Fibrosarcoma; Immunohistochemistry; p53; Soft tissue sarcoma; Xenograft

Indexed keywords

EOSIN; HEMATOXYLIN; MONOCLONAL ANTIBODY; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FIBROSARCOMA; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; IN VIVO STUDY; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FIBROSARCOMA; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; MUTATION; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34247153143     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Casali PG and Picei P: Adjuvant chemotherapy for soft tissue sarcoma. Curr Opin Oncol 17(4): 361-365, 2005.
2. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apicezmerly H, Serriano D and Picei P: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomised cooperative trial. J Clin Oncol 19: 350-362, 2001.
3. Matushansky I and Maki RG: Mechanisms of sarcomagenesis. Hematol Oncol Clin N 19(3): 427-449, 2005.
4. Fletcher JA: Molecular biology and cytogenetics of soft tissue sarcomas: relevance for targeted therapies. Cancer Treat Res 120: 99-116, 2004.
5. Hiekan TJ and Das Gupta TK: Mutant p53 expression: a marker of diminished survival in well-differentiated soft tissue sarcoma. Clin Cancer Res 2(8): 1391-1395, 1996.
6. Creager AJ, Cohen JA and Geradts J: Aberrant expression of cell-cycle regulatory proteins in human mesenchymal neoplasia. Cancer Detect Prev 25(2): 125-131, 2001.
7. Vojtesek B, Bartek J, Midgley CA and Lane DP: An immunohistochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitome mapping using recombinant p53. J Immunol Meth 151: 237-244, 1992.
8. Sherr CJ and McCormick F: The RB and p53 pathways in cancer. Cancer Cell 2(2): 103-112, 2002.
9. Wang S and El-Deiry WS: The p53 pathway: targets for the development of novel cancer therapeutics. Cancer Treat Res 119: 175-187, 2004.
10. Busand LR, Ow KT, Russell PJ, Crowe PJ and Yang J-L: Expression of insulin-like growth factor mitogenic signals in adult soft-tissue sarcomas: significant correlation with malignant potential. Virchows Arch 444: 142-148, 2004.
11. Maeda T, Nishimura N, Nakamura H and Sano K: p21 (WAF1/Cip1/Sdi1/Pic1) mRNA is expressed in neuroblastoma cell lines but not in Ewing's sarcoma and primitive neuroectodermal tumor cell lines. Acta Paediatr Japon 39(5): 590-594, 1997.
12. Mousses S, Gokgoz N, Wunder JS, Ozcelik H, Bull S and Bell RS, Andrulis IL: p53 missense but not truncation mutations are associated with low levels of p21(CIP1/WAF1) mRNA expression in primary human sarcomas. Brit J Cancer 84(12): 1635-1639, 2001.
13. Shats I, Milyavsky M, Erez N and Rotter V: The murine telomerase catalytic subunit shares the PAb-240 mutant specific epitope of the p53 protein. FEBS Lett 546: 321-324, 2003.
14. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P and Ladanyi M: Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 23(3): 548-558, 2005.
15. Hisaoka M, Okamoto S, Morimitsu Y, Tsuji S and Hashimoto H: Molecular abnormalities of the p53 pathway in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Virchows Archiv 433(4): 323-329, 1998.
16. Rieske P, Bartkowiak JK, Szadowska AM, Olborski B, Harezga-Bal B and Debiec-Rychter M: A comparative study of P53/MDM2 gene alterations and P53/MDM2 protein immunoreactivity in soft-tissue sarcomas. J Exp Clin Cane Res 18(3): 403-416, 1999.
17. Lee CS, Clarke RA, Tran KT, Kearsley JH and Chou ST: nm23 protein expression and p53 immunoreactivity in cutaneous fibrohistiocytic tumors. Pathology 31(2): 123-126, 1999.
18. Schneider-Stock R, Ziegler A, Haeckel C, Franke DS, Rys J and Roessner A: Prognostic relevance of p53 alterations and Mib-1 proliferation index in subgroups of primary liposarcomas. Clin Cancer Res 5(10): 2830-2835, 1999.
19. Oda Y, Yamamoto H, Takahira T, Kobayashi C, Kawaguchi K, Tateishi N, Nozuka Y, Tamiya S, Tanaka K, Matsuda S, Yokoyama R, Iwamoto Y and Tsuneyoshi M: Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. J Pathol 207(4): 410-421, 2005.
20. Takahashi Y, Oda Y, Kawaguchi K-I, Tamiya S, Yamamoto H, Suita S and Tsuneyoshi M: Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Modern Pathol 17: 660-669, 2004.
21. Takahira T, Oda Y, Tamiya S, Yamamoto H, Kawaguchi K, Kobayashi C, Oda S, Iwamoto Y and Tsuneyoshi M: Microsatellite instability and p53 mutation associated with tumor progression in dermatofibrosarcoma protuberans. Hum Pathol 35(2): 240-245, 2004.
22. Gaumann A, Tews DS, Mayer E, Dahm M, Petrow PK, Otto M, Kirkpatrick CJ and Kriegsmann J: Expression of apoptosis-related proteins, p53, and DNA fragmentation in sarcomas of the pulmonary artery. Cancer 92(5): 1237-1244, 2001.
23. Ottaiano A, De Chiara A, Fazioli F, Talamanca AA, Mori S, Botti G, Milano A and Apice G: Biological prognostic factors in adult soft tissue sarcomas. Anticancer Res 25(6C): 4519-4526, 2005.
24. Yang J-L Seetoo D-Q, Wang Y, Ranson M, Berney CR, Ham JH, Russell PJ and Crowe PJ: Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer (Pred Oncol) 89: 431-439, 2000.
25. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA and Friend SH: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238, 1990.
26. Legros Y, Lafon C and Soussi T: Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. Oncogene 9: 2071-2076, 1994.
27. Gannon JV, Greaves R, Iggo R and Lane DP: Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9: 1595-1602, 1990.
28. Harlow E, Crawford LV, Pim DC and Williamson NM: Monoclonal antibodies specific for simian virus 40 tumor antigens. J Virol 39: 861-869, 1981.
29. Crawford L and Harlow E: Uniform nomenclature for monoclonal antibodies directed against virus-coded proteins of simian virus 40 and polyoma virus. J Virol 41: 709-711, 1982.
30. Ball RK, Siegl B, Quellhorst S, Brandner G and Braun DG: Monoclonal antibodies against simian virus 40 nuclear large T tumor antigen: epitope mapping, papova virus cross-reaction and cell surface staining. EMBO J 3: 1485-1491, 1984.
31. Shi S-R, Cote RJ and Taylor CR: Antigen retrieval immunohistochemistry: past, present and future. J Histochem Cytochem 45: 327-344, 1997.
32. Jannot CB and Hynes NE: Characterisation of scFv-421, a single-chain antibody targeted to p53. Biochem Biophys Res Co 230: 242-246, 1997.
33. Stefanou DG, Nonni AV, Kalpouzos G, Evangelou A and Agnantis NJ: Immunophenotype, ras oncogenes and p53 oncosuppressor gene in benzo(a)pyrene induced malignant soft tissue tumours in Wistar rats. In Vivo 12(5): 511-521, 1998.
34. Berger M, Stahl N, Del Sal G and Haupt Y: Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage. Mol Cell Biol 25(13): 5380-5388, 2005.
35. El-Hizawi S, Lagowski JP, Kulesz-Martin M and Albor A: Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins. Cancer Res 62: 3264-3270, 2002.
36. Vordermark D, Menke DR and Brown JM: Similar radiation sensitivities of acutely and chronically hypoxic cells in HT 1080 fibrosarcoma xenografts. Radiat Res 159(1): 94-101, 2003.
37. Stuben G, Stuschke M, Knuhmann K, Horsman MR and Sack H: The effect of combined nicotinamide and carbogen treatments in human tumour xenografts: oxygenation and tumour control studies. Radiother Oncol 48(2): 143-148, 1998.
38. Michigami T, Yamato H, Mushiake S, Nakayama M, Yoneda A, Satomura K, Imura K and Ozono K: Hypercalcaemia associated with infantile fibrosarcoma producing parathyroid hormone-related protein. J Clinic Endocr Metab 81: 1090-1095, 1996.
39. Huang P, Allam A, Taghian A, Ruka W, Freeman J, Duffy M and Suit MD: Quantitative comparison of xenotransplantation of a human soft tissue sarcoma into the subcutaneous tissue of normal, postincision, and postincision plus indomethacin-treated nude mice. J Surg Oncol 58(4): 257-262, 1995.
40. Schmidt U, Donhuijsen K, Metz KA and Leder LD: Variability of differentiation patterns in xenotransplanted spindle cell sarcomas: a histomorphological, immunohistochemical, and ultrastructural study. Ultrastruct Pathol 20(2): 131-140, 1996.